Trials / Active Not Recruiting
Active Not RecruitingNCT03083288
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging) will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and treatment response, in subjects undergoing neoadjuvant therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]FluorThanatrace | \[18F\]FluorThanatrace is a radiotracer for PET/CT |
Timeline
- Start date
- 2017-02-22
- Primary completion
- 2026-02-22
- Completion
- 2026-02-22
- First posted
- 2017-03-20
- Last updated
- 2025-09-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03083288. Inclusion in this directory is not an endorsement.